Glaxosmithkline | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Amgen USD 11.97B 2.96B 2024-12
AstraZeneca USD 5.49B 691M 2024-12
Aurora Cannabis CAD 108.71M 23.79M 2024-12
Bausch Health Companies USD 719M 124M 2024-09
Bristol-Myers Squibb USD 10.35B 2.46B 2024-12
Canopy Growth CAD 16.31M 69.8M 2024-12
Corcept Therapeutics USD 127.66M 9.62M 2024-12
Drreddys Laboratories INR 1.1B 743M 2024-12
Eli Lilly USD 3.27B 100.6M 2024-12
GlaxoSmithKline GBP 3.87B 678M 2024-12
Glaxosmithkline GBP 3.87B 678M 2024-12
Indivior 288M 14M 2024-09
J&J USD 6.12B 1.28B 2024-12
Merck USD 13.24B 1.35B 2024-12
Novartis USD 8.87B 4.74B 2024-12
Pacira USD 276.77M 30.81M 2024-12
Perrigo USD 558.8M 904.7M 2024-12
Pfizer USD 1.04B 49M 2024-12
Prestige Brands USD 50.87M 666K 2024-12
Roche Holding CHF 6.98B 2.15B 2024-12
Sanofi 6.8B 1.92B 2024-06
Supernus Pharmaceuticals USD 69.33M 37.66M 2024-12
Takeda JPY 494.13B 364.89B 2024-12
Teva Pharmaceutical Industries USD 3.3B 19M 2024-12
Zoetis USD 1.98B 275M 2024-12



Glaxosmithkline Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2025.